Mechanisms and emerging strategies for irinotecan-induced diarrhea
S Xu, H Lan, C Huang, X Ge, J Zhu - European Journal of Pharmacology, 2024 - Elsevier
Irinotecan (also known as CPT-11) is a topoisomerase I inhibitor first approved for clinical
use as an anticancer agent in 1996. Over the past more than two decades, it has been …
use as an anticancer agent in 1996. Over the past more than two decades, it has been …
Mechanisms and emerging strategies for irinotecan-induced diarrhea
S Xu, H Lan, C Huang, X Ge, J Zhu - European journal of … - pubmed.ncbi.nlm.nih.gov
Irinotecan (also known as CPT-11) is a topoisomerase I inhibitor first approved for clinical
use as an anticancer agent in 1996. Over the past more than two decades, it has been …
use as an anticancer agent in 1996. Over the past more than two decades, it has been …
Mechanisms and emerging strategies for irinotecan-induced diarrhea.
S Xu, H Lan, C Huang, X Ge, J Zhu - European Journal of …, 2024 - europepmc.org
Irinotecan (also known as CPT-11) is a topoisomerase I inhibitor first approved for clinical
use as an anticancer agent in 1996. Over the past more than two decades, it has been …
use as an anticancer agent in 1996. Over the past more than two decades, it has been …